Diarrhoea initiates during the first four weeks of treatment, after which the incidence notably decreases [15,49]
Clinical trial data have generated significant interest in retatrutide because of its substantial weight-loss results, including Phase 3 findings showing average body weight reductions of more than 30% at the highest studied dose over 80 weeks
Severe abdominal pain : Particularly if constant, worsening, or localized to one area, which could indicate complications such as pancreatitis (severe pain often radiating to the back) or bowel obstruction
GLP-1 medications offer several important benefits for individuals looking to lose weight
These include situations where metformin is ineffective, contraindicated, or when patients fail to reach their target glycemic control despite treatment with metformin and other medications
Identification of a prolonged action molecular GLP-1R agonist for the treatment of femoral defects